ArticleJournal of inflammation research2025
Qijie Xiaopi Decoction Attenuates Gastric Mucosal Injury in PLGC Rats by Inducing Autophagy and Apoptosis Through PI3K/AKT/mTOR Pathway Inhibition.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the Wnt/β-catenin pathway: veratramine mitigates MNNG-induced gastric precancerous lesions.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Precancerous lesions of gastric cancer (PLGC) represent a crucial juncture in the transformation from gastritis to gastric cancer. Qijie Xiaopi Decoction (QJXPD), a Chinese herbal medicine formulation that has been applied in clinical practice to manage PLGC, which is capable of effectively relieving the symptoms experienced by patients such conditions. However, its mechanism of action remains unclear. The aim of this study is to elucidate the mechanism of action of QJXPD in the treatment of PLGC. Methods: Ultra-high-performance liquid chromatography coupled with hybrid quadrupole-orbitrap tandem mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS) was employed to pinpoint the chemical components of QJXPD. On this basis, network pharmacology and molecular docking were employed to pinpoint the main ingredients, probable targets, and associated pathways of QJXPD in treating of PLGC. A PLGC rat model was replicated using a compound modeling method mainly based on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), to observe the therapeutic effects of QJXPD on PLGC. Results: The undiluted QJXPD solution contained 1069 compounds. Network pharmacology analysis revealed that QJXPD's anti-PLGC effects involved 119 active ingredients and 332 potential targets, primarily enriched in the PI3K/AKT pathway. Protein-protein interaction (PPI) analysis suggested that TP53, AKT1, SRC, STAT3, and EGFR were the key targets. Through molecular docking, it was discovered that the core targets exhibited a strong binding affinity with the primary active ingredients. Animal experiments have verified that QJXPD can significantly improve the general condition in PLGC rats, increase body weight, repair the damaged gastric mucosa and diminish the inflammatory infiltration, induce apoptosis of gastric mucosal cells, upregulate the expression of LC3, Beclin-1, and Bax and downregulate the expression of p62 and Bcl-2. The PI3K/AKT/mTOR pathway was inhibited by QJXPD. Conclusion: QJXPD effectively alleviated the pathological injury of gastric mucosa in PLGC rats by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing cellular autophagy and apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.